FrancophonIA/ELRC3.0 huggingface dataset:
English: The recommended dose is one tablet of Eliquis 2.5 mg twice a day if: - you have severely reduced kidney function - two or more of the following apply to you: - your blood test results suggest poor kidney function (value of serum creatinine is 1.5 mg/dL (133 micromole/L) or greater) - you are 80 years old or older - your weight is 60 kg or lower.
Croatian: Preporučena doza je jedna Eliquis 2,5 mg tableta dvaput na dan ako: imate značajno smanjenu bubrežnu funkciju se dvije ili više od sljedećih tvrdnja odnose na Vas: - Vaši krvni nalazi ukazuju na slabu bubrežnu funkciju (vrijednost kreatinina u serumu je
English: It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B).
Croatian: U bolesnika s blagim ili umjerenim oštećenjem jetrene funkcije (Child Pugh stadij A ili B) lijek treba primjenjivati uz oprez.
English: Retroperitoneal haemorrhage
Croatian: Retroperitonealno krvarenje rijetko nepoznato
English: In the study, apixaban was shown to be non-inferior to enoxaparin/warfarin in the combined primary endpoint of adjudicated recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death (see Table 10).
Croatian: U ispitivanju, apiksaban nije bio inferioran enoksaparinu/varfarinu u kombiniranom primarnom ishodu utvrđenog ponavljajućeg simptomatskog VTE (nefatalna DVT ili nefatalna PE) ili smrtnom ishodu povezanom s VTE (vidjeti Tablicu 10).
English: Minor
Croatian: Manja
English: - Low blood pressure which may make you feel faint or have a quickened heartbeat - Bleeding: - in your eyes - in your mouth or blood in your spit when coughing - bright/red blood in the stools - tests showing blood in the stools or in the urine - bleeding occurring after any operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site - from a haemorrhoid - into a muscle - Itching - Hair loss - Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing.
Croatian: Nizak krvni tlak zbog kojega možete imati osjećaj da ćete se onesvijestiti ili Vam srce može početi ubrzano kucati - Krvarenje: - u očima - u ustima ili krv u ispljuvku kod iskašljavanja - svijetla/crvena krv u stolici - pretrage koje pokazuju krv u stolici ili u mokraći - krvarenje nakon operacije, uključujući nastanak modrica i oticanje, istjecanje krvi ili tekućine iz kirurške rane/reza (iscjedak iz rane) ili s mjesta primjene injekcije - iz hemoroida - u mišić - Svrbež - Gubitak kose - Alergijske reakcije (preosjetljivost) koje mogu izazvati: oticanje lica, usana, usta, jezika i/ili grla i otežano disanje.
English: Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was coadministered with ASA 325 mg once a day.
Croatian: Kod istodobne primjene apiksabana i ASK-a u dozi od 325 mg jedanput na dan nisu primijećene farmakokinetičke ili farmakodinamičke interakcije.
English: • Patient Alert Cards
Croatian: • Vodič za propisivača • Kartice s upozorenjima za bolesnika
English: Table 10: Efficacy Results in the AMPLIFY Study Apixaban N=2,609 n (%)
Croatian: Tablica 10: Rezultati djelotvornosti u ispitivanju AMPLIFY Apiksaban N=2609 n (%)
English: Table 8: Efficacy Results in the AMPLIFY Study Apixaban N=2,609 n (%)
Croatian: Tablica 8: Rezultati djelotvornosti u ispitivanju AMPLIFY Apiksaban N=2609 n (%)
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 2.5 mg apixaban.
Croatian: Jedna filmom obložena tableta sadrži 2,5 mg apiksabana.
English: VTE-related death
Croatian: Smrtni ishod povezan s VTE
English: Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and Cmax, respectively.
Croatian: Primjena naproksena (jedna doza od 500 mg), koji inhibira P-gp-a, ali ne i CYP3A4, povećala je srednju vrijednost AUC-a apiksabana 1,5 puta, a vrijednost Cmax 1,6 puta.
English: - for the prevention of VTE in elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE, apixaban should be used with caution;
Croatian: - u prevenciji VTE kod elektivnog kirurškog zahvata ugradnje endoproteze kuka ili koljena, u prevenciji moždanog udara i sistemske embolije u bolesnika s nevalvularnom fibrilacijom atrija i u prevenciji ponavljajućih DVT i PE apiksaban treba primjenjivati uz oprez;
English: Prevention of VTE (VTEp): elective hip or knee replacement surgery The recommended dose of apixaban is 2.5 mg taken orally twice daily.
Croatian: Prevencija VTE: elektivni kirurški zahvat ugradnje endoproteze koljena ili kuka 2,5 mg dva puta na dan
English: Pruritus
Croatian: pvrijednost
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON 5 mg
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU
English: Pink, oval tablets debossed with 894 on one side and 5 on the other side.
Croatian: Filmom obložena tableta (tableta) Ovalne tablete ružičaste boje, s utisnutom oznakom 894 s jedne i 5 s druge strane.
English: - Bleeding: - in your brain or in your spinal column - in your mouth or blood in your spit when coughing - into your abdomen, or from the vagina - bright/red blood in the stools - bleeding occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site - from a haemorrhoid - tests showing blood in the stools or in the urine - Reduced number of platelets in your blood (which can affect clotting) - Blood tests may show: - abnormal liver function - an increase in some liver enzymes - an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes - Skin rash - Itching - Hair loss - Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or throat and difficulty breathing.
Croatian: - Krvarenje: - u mozgu ili kralježnici - u ustima ili krv u ispljuvku kod iskašljavanja - u trbuhu ili iz vagine - svijetla/crvena krv u stolici - krvarenje nakon operacije, uključujući nastanak modrica i oticanje, istjecanje krvi ili tekućine iz kirurške rane/reza (iscjedak iz rane) ili s mjesta primjene injekcije - iz hemoroida - pretrage koje pokazuju krv u stolici ili u mokraći - Smanjen broj trombocita u krvi (može utjecati na zgrušavanje) - Krvna slika može pokazati: - poremećaj jetrene funkcije - povišene vrijednosti nekih jetrenih enzima - povišene vrijednosti bilirubina, koji nastaje razgradnjom crvenih krvnih stanica i zbog kojeg koža i oči mogu poprimiti žutu boju - kožni osip - svrbež - gubitak kose - alergijske reakcije (preosjetljivost) koje mogu izazvati: oticanje lica, usana, usta, jezika i/ili grla i otežano disanje.
English: Body weight VTEp and VTEt - No dose adjustment required (see sections 4.4 and 5.2).
Croatian: Tjelesna težina VTEp i VTEt - nije potrebno prilagođavati dozu (vidjeti dijelove 4.4 i 5.2).
English: VTE or VTE-related death
Croatian: VTE ili smrtni ishod povezan s VTE
English: Contact your doctor immediately if you become pregnant while taking Eliquis.
Croatian: Ako zatrudnite tijekom liječenja lijekom Eliquis, odmah se javite svom liječniku.
English: Table 13: Bleeding Results in the AMPLIFY-EXT Study Apixaban Apixaban Placebo
Croatian: Tablica 13: Rezultati krvarenja u ispitivanju AMPLIFY-EXT Apiksaban Apiksaban Placebo
English: Intracranial, n
Croatian: Značajno* Smrtonosno, n Intrakranijalno,
English: Placebo
Croatian: Apiksaban Placebo
English: No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was coadministered with atenolol or famotidine.
Croatian: Kod istodobne primjene apiksabana i atenolola ili famotidina nisu primijećene klinički značajne farmakokinetičke ni farmakodinamičke interakcije.
English: - for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE, apixaban should be used with caution;
Croatian: - u prevenciji moždanog udara i sistemske embolije u bolesnika s nevalvularnom fibrilacijom atrija i u prevenciji ponavljajućih DVT i PE apiksaban treba primjenjivati uz oprez;
English: Musculoskeletal and connective tissue disorders Muscle haemorrhage
Croatian: Poremećaji mišićno-koštanog sustava i vezivnog tkiva Krvarenje u mišić rijetko manje često
English: - Bleeding including: - from your nose - from your gums - blood in the urine - bruising and swelling - in your stomach, your bowel, from your rectum - in your mouth - from the vagina - Anaemia which may cause tiredness or paleness - Reduced number of platelets in your blood (which can affect clotting) - Nausea (feeling sick) - Skin rash - Blood tests may show: - an increase in gamma-glutamyltransferase (GGT) or alanine aminotransferase (ALT)
Croatian: - Krvarenje koje uključuje: - iz nosa - iz desni - krv u mokraći - nastanak modrica i oticanje - u želucu, crijevima, iz završnog dijela debelog crijeva - u ustima - iz vagine - Anemija koja može izazvati umor ili bljedoću - Smanjen broj trombocita u krvi (može utjecati na zgrušavanje) - Mučnina - Kožni osip - Krvna slika može pokazati: - povišenje gama-glutamiltransferaze (GGT-a) ili alanin aminotransferaze (ALT-a)
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 5 mg apixaban.
Croatian: Jedna filmom obložena tableta sadrži 5 mg apiksabana.
English: Table 12: Efficacy Results in the AMPLIFY-EXT Study Apixaban Apixaban Placebo
Croatian: Tablica 12: Rezultati djelotvornosti u ispitivanju AMPLIFY-EXT Apiksaban Apiksaban Placebo
English: Stroke or systemic embolism 212 (1.27) 265 (1.60) 0.79 (0.66, 0.95) Stroke Ischaemic or unspecified 162 (0.97) 175 (1.05) 0.92 (0.74, 1.13) Haemorrhagic Systemic embolism 15 (0.09) 17 (0.10) 0.87 (0.44, 1.75)
Croatian: Moždani udar ili sistemska embolija 212 (1,27) Moždani udar Ishemijski ili nespecificiran 162 (0,97) Hemoragijski Sistemska embolija
English: Traumatic haemorrhage
Croatian: Ishodi krvarenja
English: Investigations Occult blood positive
Croatian: Pozitivno okultno krvarenje manje često manje često
English: Table 3: Predicted Apixaban Steady-state Exposure and Anti-Xa Activity
Croatian: Tablica 3: Predviđena izloženost apiksabanu u stanju dinamičke ravnoteže i anti-Xa aktivnost Apiksaban Cmax (ng/ml)
English: The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis.
Croatian: Postoperativna primjena trajnog epiduralnog katetera ili istodobna primjena lijekova koji utječu na hemostazu mogu povećati rizik od navedenih događaja.
English: NAME OF THE MEDICINAL PRODUCT Eliquis 2.5 mg film-coated tablets
Croatian: Eliquis 2,5 mg filmom obložene tablete
English: Table 10: Efficacy Results in the AMPLIFY-EXT Study Apixaban Apixaban Placebo
Croatian: Tablica 10: Rezultati djelotvornosti u ispitivanju AMPLIFY-EXT Apiksaban Apiksaban Placebo
English: Yellow, round tablets debossed with 893 on one side and 2½ on the other side.
Croatian: Filmom obložena tableta (tableta) Okrugle tablete žute boje, s utisnutom oznakom 893 s jedne i 2½ s druge strane.
English: NAME OF THE MEDICINAL PRODUCT Eliquis 5 mg film-coated tablets
Croatian: Eliquis 5 mg filmom obložene tablete
English: In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic, ischaemic or unspecified) or systemic embolism (see Table 8) compared to ASA.
Croatian: U ispitivanju je apiksaban bio statistički značajno uspješniji u primarnom ishodu - sprječavanju moždanog udara (hemoragijskog, ishemijskog ili nespecificiranog) ili sistemske embolije (vidjeti Tablicu 8) u usporedbi s ASK-om.
English: Apixaban demonstrates linear pharmacokinetics with dose proportional increases in exposure for oral doses up to 10 mg. At doses ≥ 25 mg apixaban displays dissolution limited absorption with decreased bioavailability.
Croatian: Kod peroralnih doza do 10 mg, apiksaban pokazuje linearnu farmakokinetiku i porast izloženosti proporcionalan dozi.
English: - medicines for high blood pressure or heart problems (e.g., diltiazem)
Croatian: - protuupalni lijekovi ili lijekovi za ublažavanje bolova (npr. acetilsalicilatna kiselina ili naproksen).
English: Table 6: Key Efficacy Outcomes in Patients with Atrial Fibrillation in the AVERROES Study Apixaban N = 2,807 n (%/year)
Croatian: Tablica 6: Ključni rezultati djelotvornosti u bolesnika s fibrilacijom atrija u ispitivanju AVERROES Apiksaban N = 2807 n (% na godinu)
English: Table 8: Key Efficacy Outcomes in Patients with Atrial Fibrillation in the AVERROES Study Apixaban N = 2,807 n (%/year)
Croatian: Tablica 8: Ključni rezultati djelotvornosti u bolesnika s fibrilacijom atrija u ispitivanju AVERROES Apiksaban N = 2807 n (% na godinu)
English: Table 5: Secondary Endpoints in Patients with Atrial Fibrillation in the ARISTOTLE Study Apixaban N = 9,088 n (%/year)
Croatian: Tablica 5: Sekundarne mjere ishoda u bolesnika s fibrilacijom atrija u ispitivanju ARISTOTLE Apiksaban N = 9088 n (% na godinu)
English: Naproxen (500 mg), an inhibitor of P-gp, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and Cmax, respectively.
Croatian: Primjena naproksena (500 mg), inhibitora P-gp-a, povećala je srednju vrijednost AUC-a apiksabana 1,5 puta, a vrijednost Cmax 1,6 puta.
English: - in your brain or in your spinal column - in your mouth or blood in your spit when coughing - into your abdomen, or from the vagina - bright/red blood in the stools - bleeding occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site - from a haemorrhoid - tests showing blood in the stools or in the urine - Reduced number of platelets in your blood (which can affect clotting) - Blood tests may show: - abnormal liver function - an increase in some liver enzymes - an increase in bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes.
Croatian: - Krvarenje: - u mozgu ili kralježnici - u ustima ili krv u ispljuvku kod iskašljavanja - u trbuh ili iz vagine - svijetla/crvena krv u stolici krvarenje nakon operacije, uključujući nastanak modrica i oticanje, istjecanje krvi ili tekućine iz kirurške rane/reza (iscjedak iz rane) ili s mjesta primjene injekcije - iz hemoroida - pretrage koje pokazuju krv u stolici ili u mokraći - Smanjen broj trombocita u krvi (može utjecati na zgrušavanje) - Krvna slika može pokazati: - poremećaj funkcije jetre - poremećaj vrijednosti nekih jetrenih enzima - povišene vrijednosti bilirubina, koji nastaje razgradnjom crvenih krvnih stanica i zbog kojeg koža i oči mogu poprimiti žutu boju
English: Table 9: Bleeding Events in Patients with Atrial Fibrillation in the AVERROES Study Apixaban N = 2,798 n(%/year)
Croatian: Tablica 9: Krvarenja u bolesnika s fibrilacijom atrija u ispitivanju AVERROES Apiksaban N = 2798 n (% na godinu)
English: Table 4: Efficacy Outcomes in Patients with Atrial Fibrillation in the ARISTOTLE Study Apixaban N=9,120 n (%/yr)
Croatian: Tablica 4: Rezultati djelotvornosti u bolesnika s fibrilacijom atrija u ispitivanju ARISTOTLE Apiksaban N=9120 n (% na godinu)
English: Table 7: Bleeding Events in Patients with Atrial Fibrillation in the AVERROES Study Apixaban N = 2,798 n(%/year)
Croatian: Tablica 7: Krvarenja u bolesnika s fibrilacijom atrija u ispitivanju AVERROES Apiksaban N = 2798 n (% na godinu)
English: NAME OF THE MEDICINAL PRODUCT Eliquis 2.5 mg tablets apixaban
Croatian: Eliquis 2,5 mg tablete apiksaban
English: Enoxaparin 40 mg sc once daily 12 ± 2 d p-value
Croatian: Enoksaparin 40 mg s.c. jedanput na dan 12 ± 2 d pvrijednost
English: Table 6: Efficacy Outcomes in Patients with Atrial Fibrillation in the ARISTOTLE Study Apixaban N=9,120 n (%/yr)
Croatian: Tablica 6: Rezultati djelotvornosti u bolesnika s fibrilacijom atrija u ispitivanju ARISTOTLE Apiksaban N=9120 n (% na godinu)
English: In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic, ischaemic or unspecified) or systemic embolism (see Table 6) compared to ASA.
Croatian: U ispitivanju je apiksaban bio statistički značajno uspješniji u primarnom ishodu - sprječavanju moždanog udara (hemoragijskog, ishemijskog ili nespecificiranog) ili sistemske embolije (vidjeti Tablicu 6) u usporedbi s ASK-om.
English: NAME OF THE MEDICINAL PRODUCT Eliquis 5 mg tablets apixaban
Croatian: Eliquis 5 mg tablete apiksaban
English: Apixaban demonstrated a statistically superior reduction in the primary endpoint, a composite of all VTE/all cause death, and in the Major VTE endpoint, a composite of proximal DVT, non-fatal PE, and VTE-related death, compared to enoxaparin in both elective hip or knee replacement surgery (see Table 4).
Croatian: U elektivnim kirurškim zahvatima ugradnje endoproteze kuka i koljena apiksaban je bio statistički uspješniji od enoksaparina u redukciji primarnog ishoda (kombinacija svih venskih tromboembolijskih događaja (VTE) i smrti zbog bilo kojeg razloga) te redukciji glavnog VTE ishoda (kombinacija proksimalne duboke venske tromboze (DVT), nesmrtonosne plućne embolije (PE) i smrtnog ishoda povezanog s venskom tromboembolijom) (vidjeti Tablicu 4).
English: Respiratory, thoracic and mediastinal disorders Epistaxis
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja Epistaksa često često
English: Table 7: Secondary Endpoints in Patients with Atrial Fibrillation in the ARISTOTLE Study Apixaban N = 9,088 n (%/year)
Croatian: Tablica 7: Sekundarne mjere ishoda u bolesnika s fibrilacijom atrija u ispitivanju ARISTOTLE Apiksaban N = 9088 n (% na godinu)
English: Naproxen
Croatian: Naproksen
English: NAME OF THE MEDICINAL PRODUCT Eliquis 5 mg film-coated tablets apixaban
Croatian: Eliquis 5 mg filmom obložene tablete apiksaban
English: NAME OF THE MEDICINAL PRODUCT Eliquis 2.5 mg film-coated tablets apixaban
Croatian: Eliquis 2,5 mg filmom obložene tablete apiksaban
English: Hip fracture surgery
Croatian: Kirurški zahvat zbog prijeloma kuka
English: When converting patients from Eliquis to VKA therapy, administration of Eliquis should be continued for at least 2 days after beginning VKA therapy.
Croatian: Prelazak s lijeka Eliquis na terapiju antagonistom vitamina K Tijekom prelaska s lijeka Eliquis na antagonist vitamina K, treba nastaviti primjenjivati Eliquis još barem 2 dana nakon početka liječenja antagonistom vitamina K. Nakon 2 dana istodobne primjene lijeka Eliquis i antagonista vitamina
English: Apixaban has not been studied in clinical trials in patients undergoing hip fracture surgery to evaluate efficacy and safety in these patients.
Croatian: Nisu provedena klinička ispitivanja djelotvornosti i sigurnosti primjene apiksabana u bolesnika koji su bili podvrgnuti kirurškom zahvatu zbog prijeloma kuka.
English: For example, diltiazem (360 mg once a day), considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean apixaban AUC and a 1.3-fold increase in Cmax.
Croatian: Primjerice, primjena diltiazema (360 mg jedanput na dan), koji se smatra umjereno jakim inhibitorom CYP3A4 i slabim inhibitorom
English: Rare
Croatian: Značajna
English: Clotting tests [e.g., prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT)] are affected as expected by the mechanism of action of apixaban.
Croatian: Mehanizam djelovanja apiksabana očekivano utječe na rezultate testova zgrušavanja [npr. protrombinsko vrijeme (PV), INR i aktivirano parcijalno tromboplastinsko vrijeme (aPTV)].
English: Tell your doctor immediately if you have taken more than the prescribed dose of Eliquis.
Croatian: Ako ste uzeli više od propisane doze lijeka Eliquis, odmah se obratite svom liječniku.
English: No dose adjustment for apixaban is required when coadministered with agents that are not strong inhibitors of both CYP3A4 and P-gp.
Croatian: Kod istodobne primjene s lijekovima koji nisu snažni inhibitori CYP3A4 i P-gp-a nije potrebno prilagođavati dozu apiksabana.
English: 2.5 mg twice daily
Croatian: 2,5 mg dvaput na dan
English: Bleeding: - into your abdomen or the space behind your abdominal cavity
Croatian: - Krvarenje: - u trbuh ili u prostor iza trbućne šupljine
English: - Bleeding including: - in your eyes - in your stomach or bowel - from your rectum - blood in the urine - from your nose - from your gums - bruising and swelling - Anaemia which may cause tiredness or paleness - Low blood pressure which may make you feel faint or have a quickened heartbeat - Nausea (feeling sick) - Blood tests may show: - an increase in gamma-glutamyltransferase (GGT)
Croatian: - Krvarenje koje uključuje: - iz nosa - iz desni -krv u mokraći -nastanak modrica i oticanje - u želucu, crijevima, iz završnog dijela debelog crijeva - u ustima - iz vagine - Anemija koja može izazvati umor ili bljedoću - Smanjen broj trombocita u krvi (može utjecati na zgrušavanje) - Mučnina - Kožni osip - Krvna slika može pokazati: - povišenje gama-glutamiltransferaze (GGT-a) il alanin aminotransferaze (ALT-a)
English: Switching from Eliquis to VKA therapy
Croatian: - Prelazak s antikoagulansa na Eliquis
English: Post procedural haemorrhage (including post procedural haematoma, wound haemorrhage, vessel puncture site haematoma and catheter site haemorrhage), wound secretion, incision site haemorrhage (including incision site haematoma), operative haemorrhage
Croatian: Krvarenje nakon kirurškog zahvata (uključujući hematom nakon kirurškog zahvata, krvarenje iz rane, hematom na mjestu punkcije žile i krvarenje na mjestu uvođenja katetera), sekrecija iz rane, krvarenje na mjestu reza (uključujući hematom na mjestu reza), krvarenje tijekom kirurškog zahvata manje često manje često
English: In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic or ischaemic) and systemic embolism (see Table 6) compared with warfarin.
Croatian: U ispitivanju je apiksaban bio statistički značajno uspješniji od varfarina u primarnoj mjeri ishodasprječavanju moždanog udara (hemoragijskog ili ishemijskog) i sistemske embolije (vidjeti Tablicu 6).
English: In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic or ischaemic) and systemic embolism (see Table 4) compared with warfarin.
Croatian: U ispitivanju je apiksaban bio statistički značajno uspješniji od varfarina u primarnoj mjeri ishodasprječavanju moždanog udara (hemoragijskog ili ishemijskog) i sistemske embolije (vidjeti Tablicu 4).
English: Not known Uncommon
Croatian: Intraabdominalno krvarenje nepoznato manje često nepoznato
English: - if you have a prosthetic heart valve - if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned
Croatian: - teška bolest bubrega ili ste na dijalizi - postojeće ili prijašnje jetrene tegobe Eliquis će se primjenjivati uz oprez u bolesnika koji pokazuju znakove poremećaja jetrene funkcije - ako imate protetski srčani zalistak - ako liječnik utvrdi da Vam je krvni tlak nestabilan ili je planirano drugačije liječenje ili kirurški postupak za uklanjanje krvnog ugruška iz pluća.
English: Recurrent VTE or VTErelated death
Croatian: Ponavljajući VTE ili smrtni ishod povezan s VTE
English: Mouth haemorrhage
Croatian: Kroz usta
English: Table 11: Bleeding Results in the AMPLIFY-EXT Study Apixaban Apixaban Placebo
Croatian: Tablica 11: Rezultati krvarenja u ispitivanju AMPLIFY-EXT Apiksaba n
English: Warfarin N = 9,052 n (%/year)
Croatian: Apiksaban N=2609 n (%)
English: The recommended dose is one tablet of Eliquis 2.5 mg twice a day.
Croatian: Preporučena doza apiksabana je 2,5 mg peroralno dvaput na dan.
English: 4 hours.
Croatian: 4 sata.
English: You will not have to store this medicine.
Croatian: Nećete morati čuvati ovaj lijek.
English: It will be the smallest quantity necessary to get the desired information.
Croatian: To će biti najmanja količina koja je potrebna da bi se dobila željena informacija.